Sun Of India Agrees With Sanofi Of France To Delay Marketing Generic
This article was originally published in PharmAsia News
Executive SummaryIndia's Sun Pharmaceutical Industries reached an agreement with Sanofi-Aventis to settle a U.S. case by ceasing to sell a generic of a cancer drug after June 30
You may also be interested in...
All medtech in Brazil will soon be subject to standardized industrial tariffs and development-related fiscal incentives, following a reform of rules relating to ICT across all industries.